Clinical trials: Recurrent Tumor
Mouth Sores
Post-marketing Study for the Evaluation of Profilm Mouth Sores
The study aims to assess the effect of Profilm Mouth Sores treatment for relieving symptoms caused by mouth sores. It will involve 35 participants and last around 14 days or until the sores heal, with three daily applications.
- Trial name
- NCT06741280
- Testing
- Profilm Mouth Sores
- Where
- Spain
- Volunteers
- 35 people
- Sponsor
- i+Med S.Coop.
Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia, Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia
A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia
The main objective of this study is to evaluate the safety and efficacy of SC blinatumomab in children below 12 years of age.
- Trial name
- NCT07134088
- Testing
- Blinatumomab
- Where
- 5 sites in United States, Japan
- Volunteers
- 104 people
- Sponsor
- Amgen
Ovarian Epithelial Cancer, Fallopian Tube Cancer
p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
The study objective is to investigate the efficacy and safety of p53 combined with chemotherapy (cisplatin and paclitaxel) in treatment of recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer.
- Conditions
- Ovarian Epithelial Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT02435186
- Testing
- p53 gene, Cisplatin, Paclitaxel
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shenzhen SiBiono GeneTech Co.,Ltd
Glioblastoma Multiforme
Study of Everolimus (RAD001) in Patients With Recurrent Glioblastoma Multiforme (GBM)
This study will define the safety and efficacy of Everolimus (RAD001) administered daily in patients with glioblastoma multiforme (GBM)
- Trial name
- NCT00515086
- Testing
- Everolimus, Surgery
- Where
- 8 sites in United States
- Volunteers
- 41 people
- Sponsor
- Novartis Pharmaceuticals
Endometrial Carcinoma, Serous Carcinoma
Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma
Endometrial Serous carcinoma (ESC) has similar molecular characteristics to high-grade serous ovarian carcinoma (HGSOC) and basal cell-like breast cancer, such as similar Chromosomal instability, somatic copy number variation…
- Trial name
- NCT04716686
- Testing
- Niraparib
- Where
- China
- Volunteers
- 83 people
- Sponsor
- Shandong University
Meningeal Metastasis
Evaluate the Safety, Tolerability, Biodistribution Characteristics and Preliminary Efficacy of BioTTT001
Phase Ib/II clinical study on evaluating the safety, tolerance, biodistribution characteristics and preliminary efficacy of recombinant human nsIL12 oncolytic adenovirus injection (BioTT001) in the treatment of meningeal…
- Trial name
- NCT07264569
- Testing
- BioTTT001 injection
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Henan Cancer Hospital
Breast Cancer
Radiotherapy After Mastectomy for Breast Cancer Patients at Increased Risk of Local Recurrence
STUDY DESCRIPTION: This is a single-arm study to assess the feasibility, toxicity and cosmetic outcome of partial radiotherapy of the chest wall in breast cancer patients at increased risk of local relapse submitted to…
- Trial name
- NCT03101683
- Testing
- Partial chest wall radiation therapy
- Volunteers
- 28 people
- Sponsor
- Fondazione del Piemonte per l'Oncologia
Adult B Acute Lymphoblastic Leukemia, Adult Nasal Type Extranodal NK/T-Cell Lymphoma
Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors
This phase I/II trial studies the side effects and the best dose of veliparib when given together with bendamustine hydrochloride and rituximab and to see how well they work in treating patients with lymphoma, multiple myeloma…
- Conditions
- Adult B Acute Lymphoblastic Leukemia, Adult Nasal Type Extranodal NK/T-Cell Lymphoma, Adult Solid Neoplasm, Anaplastic Large Cell Lymphoma
- Trial name
- NCT01326702
- Testing
- Bendamustine Hydrochloride, Pharmacological Study, Rituximab
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- National Cancer Institute (NCI)
Chemotherapeutic Agent Toxicity, Sarcoma
CYP3A5 Gene as a Risk Factor for Kidney Damage in Young Patients With Cancer Treated With Ifosfamide
RATIONALE: Studying the genes expressed in samples of blood from young patients with cancer treated with ifosfamide may help doctors identify risk factors for kidney damage.
- Conditions
- Chemotherapeutic Agent Toxicity, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00514345
- Testing
- gene expression analysis, polymorphism analysis, management of therapy complications
- Where
- 21 sites in Ireland, United Kingdom
- Volunteers
- 300 people
- Sponsor
- Children's Cancer and Leukaemia Group
Neuroblastoma Recurrent
Immunotherapy of Neuroblastoma Patients Using a Combination of Anti-GD2 and NK Cells
Neuroblastoma is a neoplasm of the sympathetic nervous system which affects mostly children younger than 5 years of age. It is a heterogeneous disease, with nearly 50% of patients presenting with a high-risk phenotype.
- Trial name
- NKEXPGD2 (NCT03242603)
- Testing
- Anti-GD2 in combination with NK cells
- Where
- Singapore
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- National University Hospital, Singapore
Oncolytic Virotherapy
Open Multi-cohort Study of the First Phase of Safety of a Drug Based on Double Recombinant Vaccinia Virus VV-GMCSF-Lact
Purpose of the study is to evaluate the safety, tolerability and pharmacokinetic parameters of the drug based on double recombinant vaccinia virus VV-GMCSF-Lact, in patients with recurrent/refractory metastatic breast cancer in…
- Trial name
- NCT05376527
- Testing
- Double Recombinant Vaccinia Virus VV-GMCSF-Lact
- Where
- 4 sites in Russia
- Volunteers
- 34 people
- Sponsor
- "Oncostar" LLC
Recurrent Glioblastoma
Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM
This is an open-label, phase 1b study to evaluate different approaches for CART-EGFR-IL13Ra2 dosing and further characterize the safety, feasibility, preliminary efficacy, and pharmacokinetics of CART-EGFR-IL13Ra2 cells in…
- Trial name
- NCT07209241
- Testing
- CART-EGFR-IL13Ra2 T cells
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Pennsylvania
Pancreatic Cancer
Trabectedin in Treating Patients With Metastatic Pancreatic Cancer After First-Line Chemotherapy
RATIONALE: Drugs used in chemotherapy, such as trabectedin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- PACT-18 (NCT01339754)
- Testing
- trabectedin
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- IRCCS San Raffaele
Sarcoma
Gefitinib in Treating Patients With Locally Advanced or Metastatic Synovial Sarcoma
RATIONALE: Biological therapies such as gefitinib may interfere with the growth of the tumor cells and slow the growth of synovial sarcoma.
- Trial name
- NCT00052754
- Testing
- gefitinib
- Where
- 16 sites in Belgium, France and 2 more
- Volunteers
- 48 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Colorectal Cancer Stage IV, Colorectal Cancer Metastatic
Plasma 5hmC Signatures as a Marker of Colorectal / Appendiceal Peritoneal Metastasis
Patients with peritoneal metastasis of colorectal or high grade appendiceal origin who are candidates for cytoreductive surgery with HIPEC (hyperthermic intraperitoneal chemotherapy) will be enrolled in this study.
- Conditions
- Colorectal Cancer Stage IV, Colorectal Cancer Metastatic, Colorectal Cancer, Genetics of, Appendix Cancer
- Trial name
- NCT04157322
- Testing
- prospective single arm biomarker (plasma cell-free DNA hydroxymethylation) study
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- University of Chicago
Prostate Cancer
Multimodality Phase II Study in Prostate Cancer
This is a single arm phase II study of docetaxel, prednisone, and sunitinib systemic therapy followed by salvage external beam radiation therapy for men who have experienced PSA recurrence following initial radical prostatectomy…
- Trial name
- NCT00734851
- Testing
- Docetaxel, Sunitinib, EBXRT
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Duke University
Endometrial Cancer
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
This study evaluates navtemadlin as maintenance treatment for patients with advanced or recurrent endometrial cancer (EC) who have achieved complete response or partial response on chemotherapy.
- Trial name
- NCT05797831
- Testing
- Navtemadlin
- Where
- 83 sites in United States, Austria and 15 more
- Volunteers
- 268 people
- Sponsor
- Kartos Therapeutics, Inc.
Colorectal Cancer, Metastatic Cancer
Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and/or Lung
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- ERBIFORT (NCT00557102)
- Testing
- cetuximab, filgrastim, fluorouracil
- Where
- France
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute, France
Cervical Cancer
A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
This is A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate AK104 Plus Platinum-containing Chemotherapy With or Without Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical…
- Trial name
- NCT04982237
- Testing
- AK104, paclitaxel, carboplatin
- Where
- 5 sites in China
- Volunteers
- 445 people
- Sponsor
- Akeso
Leukemia, Lymphoma
Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic Cancers
Giving chemotherapy drugs, such as fludarabine and busulfan, before a donor peripheral stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00619645
- Testing
- busulfan, cyclosporine, fludarabine phosphate
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of California, Davis
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.